ストックスクリーナーアプリを入手
1.25
5.04%
0.06
プレマーケット:
1.22
-0.03
-2.40%
Allarity Therapeutics Inc (ALLR) 最新ニュース
Aug Reactions: Will Allarity Therapeutics Inc stock recover after earningsPortfolio Risk Summary & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Earnings Miss: Can Allarity Therapeutics Inc weather a recessionCEO Change & AI Driven Stock Price Forecasts - baoquankhu1.vn
[PRE 14A] Allarity Therapeutics, Inc. Preliminary Proxy Statement - Stock Titan
ALLR: Ascendiant Capital Maintains Buy Rating, Raises Price Targ - GuruFocus
Allarity Therapeutics, Inc. (ALLR) stock price, news, quote and history - uk.finance.yahoo.com
Allarity Therapeutics Reports 2025 Financial Results, Advances Stenoparib in Ovarian and Lung Cancer with FDA Fast Track Designation - Minichart
Allarity Therapeutics posts $320k revenue, $11.2M net loss and $14.7M year-end cash (2025) - TradingView — Track All Markets
Allarity Therapeutics (NASDAQ: ALLR) cuts 2025 loss to $11.2M and posts first revenue - Stock Titan
ALLR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Allarity Therapeutics, Inc. (ALLR) Stock Price, News, Quote & History - ca.finance.yahoo.com
TON Strategy Company (VERB) Reports FY2025 Earnings - AlphaStreet
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress - Investing News Network
Allarity Therapeutics, Inc. (ALLR) Reports FY2025 Earnings - AlphaStreet
Purple Innovation, Inc. (PRPL) Reports Q4 Earnings - AlphaStreet
Allarity Therapeutics reports full year 2025 financial results and corporate progress - marketscreener.com
Market Catalysts: Is Allarity Therapeutics Inc stock forming a cup and handleWeekly Investment Report & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Allarity Therapeutics Reports Full Year 2025 Financial Results And Corporate Progress - TradingView
Cancer drug gets FDA Fast Track as Allarity says cash lasts to 2028 - Stock Titan
Stenoparib push: Allarity Therapeutics (NASDAQ: ALLR) reshapes cancer pipeline - Stock Titan
Allarity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Expands By 27.2% - Defense World
Tranche Update on Allarity Therapeutics, Inc.'s Equity Buyback Plan announced on March 3, 2025. - marketscreener.com
Shorts Report: Can Allarity Therapeutics Inc disrupt its industry2026 Market Trends & Consistent Return Strategy Ideas - baoquankhu1.vn
Former Allarity Executive Winnows SEC’s FDA Approval Scheme Suit - Bloomberg Law News
Allarity Therapeutics (ALLR) Projected to Post Quarterly Earnings on Monday - Defense World
Volume Summary: Will Allarity Therapeutics Inc stock recover after earningsDip Buying & Safe Entry Trade Signal Reports - baoquankhu1.vn
Pharma News: Can Allarity Therapeutics Inc expand its profit margins2026 Bull vs Bear & Low Volatility Stock Recommendations - baoquankhu1.vn
Allarity Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | C6D | US0167441049 - marketscreener.com
Aug Spikes: Whats the analyst consensus on Allarity Therapeutics IncGlobal Markets & AI Driven Stock Reports - baoquankhu1.vn
Inflation Data: Can Allarity Therapeutics Inc disrupt its industry2026 Technicals & Technical Entry and Exit Tips - baoquankhu1.vn
MACD Signal: Can Allarity Therapeutics Inc expand its profit marginsTrade Performance Summary & Stock Market Timing Techniques - baoquankhu1.vn
Allarity’s Terminated Breast Cancer Trial Signals Setback for DRP-Guided Chemotherapy - TipRanks
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates - GuruFocus
Big Picture: Is Allarity Therapeutics Inc backed by strong institutional buying2026 Momentum Check & Community Verified Watchlist Alerts - baoquankhu1.vn
Allarity Therapeutics Secures $20 Million Debt Financing to Advance Stenoparib Toward FDA Approval and Extend Cash Runway to 2028 - Minichart
Allarity closes $20M non-convertible debt to fund stenoparib Phase 2 and extend runway - TradingView
Allarity Therapeutics (NASDAQ: ALLR) closes $20M debt to fund trials - Stock Titan
Allarity closes $20M financing for stenoparib advancement - Yahoo Finance
Allarity secures $20M debt financing to extend cash runway By Investing.com - Investing.com South Africa
Allarity Therapeutics, Inc. announced that it has received $20.93 million in funding - marketscreener.com
Allarity Therapeutics, Inc. Closes $20 Million Non-Convertible Debt Financing - marketscreener.com
Allarity secures $20M debt financing to extend cash runway - Investing.com
Allarity Therapeutics Secures $20 Million Structured Note Financing - TipRanks
Allarity Therapeutics Secures $20.9M Notes Financing From Streeterville, With Collateral Agreements - TradingView
Allarity Therapeutics closes $20 million financing to accelerate the advance of stenoparib toward FDA approval and commercialization - marketscreener.com
Allarity Therapeutics (ALLR) enters $20.93M secured note deal with covenants - Stock Titan
Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib ... - Bluefield Daily Telegraph
Allarity Therapeutics Closes $20 Million Financing To Accelerate The Advance Of Stenoparib Toward FDA Approval And Commercialization - TradingView
Allarity Therapeutics Closes $20 Million Financing to - GlobeNewswire
Aug Analyst Calls: What is Allarity Therapeutics Incs 5 year growth outlookJuly 2025 Short Interest & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Retail Trends: What are REV Group Incs earnings expectationsJuly 2025 Chart Watch & Real-Time Stock Entry Alerts - baoquankhu1.vn
ALLR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Allarity Therapeutics doses first patients in VA-funded small cell lung cancer trial - Mugglehead Investment Magazine
Why analysts upgrade Allarity Therapeutics Inc. stockRate Hike & Real-Time Buy Zone Alerts - mfd.ru
Allarity Therapeutics doses first patients in VA-funded Phase 2 SCLC trial - TradingView
VA-funded Phase 2 stenoparib trial begins for Allarity (NASDAQ: ALLR) - Stock Titan
First patients dosed in VA-funded stenoparib trial for lung cancer - Investing.com Australia
Allarity Therapeutics Doses First Patients in Phase 2 Lung Cancer Trial - marketscreener.com
Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need - The Manila Times
Allarity Therapeutics Initiates VA-Funded Phase 2 Trial of Stenoparib and Temozolomide for Relapsed Small Cell Lung Cancer - Quiver Quantitative
VA lung cancer trial tests new drug combo for patients with few options - Stock Titan
What is Allarity Therapeutics Inc. s 5 year growth outlook2025 Key Lessons & Detailed Earnings Play Strategies - mfd.ru
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):